Clinical Trial Search

Primary: Proportion of Accurately Identified Subject Pre- and Post-treatment Photographs by at Least Two of the Three Blinded Independent Evaluators. — 26 Participants

Primary: Change in Forgotten Joint Score After 2 Years From Baseline — 50.1; 46.4 score on a scale

Primary: Average Lux During Intervention and Control Periods at the Facility Level — 394.2; 97.4 Lux

Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants

Primary: Composite of: Cardiovascular Death*, Re-myocardial Infarct, Re-hospitalization for Heart Failure (HF) and Congestive Heart Failure (CHF), Resuscitation or ICD…

Primary: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events: Monotherapy — 3; 7; 2; 0 Participants

Primary: Change in Cold Pressor Test (CPT) Latency — 21.40; 10.94; 2.07; 15.17 percent change from Day 1 baseline

Primary: Packed Red Blood Cells Equivalents Units Transfused (1 Whole Blood Unit Treated as 1 Packed Red Blood Cell Unit and 1 Fresh Frozen Plasma Unit) — 3.8; 5.7 units

Primary: Patient Reported Swallowing Related Quality of Life — 50; 40; 40 score on a scale

Primary: Oldenburg Sentence Test — -6.6; -1.1; -3.5 dB — p=<0.001

Primary: Metformin Area Under the Concentration vs. Time Curve (AUC) — 830 mcg*h/L

Primary: Self-reported Perceived Value of Patient Priorities Care (PPC) Approach — 75; 85.7 percentage of participants

Primary: Radiological Progression-free Survival (rPFS) Assessed by Central Review — NA; 25.0 Months — p=<0.0001

Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -0.04; -0.5 percent neutrophils — p=> 0.99

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 31 score on a scale